← Oncology Approval Tracker

FDA DECISION ·

Jobevne

bevacizumab-nwgd · Biocon Biologics

Biosimilar approvalBiosimilarMultiple solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Avastin biosimilar for the labeled regimens in metastatic colorectal cancer, eligible nonsquamous NSCLC, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

LAMPGEN ANALYSIS

Why it matters

This anti-VEGF biosimilar adds a bevacizumab sourcing option across several solid tumor settings.

What research teams should watch

Check the precise label for each regimen and preserve product and lot traceability, blood pressure monitoring, and perioperative holds.

PRIMARY RECORDS

Sources